Summit Therapeutics
SMMT
$3.86
Share price
8.73%
Change (1 day)
192.42%
Change (1 year)
Categories
Summit Therapeutics (SMMT) - P/B ratio
P/B ratio as of April 2024 : 34.9
According to Summit Therapeutics
's latest financial reports the company has a price-to-book ratio of 34.9.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Summit Therapeutics - P/B ratio (from 2020 to 2020)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 23.5 | 248.52% |
| 2022-12-31 | 6.76 | 114.05% |
| 2021-12-31 | 3.16 | -35.14% |
| 2020-12-31 | 4.87 | 102.41% |
| 2019-12-31 | 2.40 | 475.27% |
| 2018-12-31 | 0.4179 | -92.9% |
| 2017-12-31 | 5.88 | -90.92% |
| 2016-12-31 | 64.8 | 2737.61% |
| 2015-12-31 | 2.28 | |
| 2014-12-31 | N/A | |
| 2013-12-31 | N/A | |
| 2012-12-31 | N/A | |
| 2011-12-31 | N/A | |
| 2010-12-31 | N/A | |
| 2009-12-31 | N/A | |
| 2008-12-31 | N/A | |
| 2007-12-31 | N/A | |
| 2006-12-31 | N/A | |
| 2005-12-31 | N/A | |
| 2004-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Sarepta Therapeutics
SRPT | 14.2 | -59.38% | 🇺🇸 USA |
 Merrimack Pharmaceuticals MACK | 11.4 | -67.25% | 🇺🇸 USA |
 Coherus BioSciences
CHRS | -1.20 | -103.43% | 🇺🇸 USA |